AI Article Synopsis
- Locoregional therapies (LRTs) for hepatocellular carcinoma include ablative methods like microwave and radiofrequency ablation, as well as embolic techniques such as transarterial chemoembolization and radioembolization.
- These therapies aim to either cure, bridge, or downstage patients, but they often face challenges with high post-treatment recurrence rates.
- Current research suggests that combining LRTs with systemic therapy could enhance disease control and improve outcomes for patients with liver cancer.
Article Abstract
Embolic and ablative locoregional therapies (LRTs) for hepatocellular carcinoma are widely used to cure, bridge, or downstage patients for more definitive therapies. Common ablative therapies include microwave ablation and radiofrequency ablation, while embolic options include transarterial chemoembolization and 90Y transarterial radioembolization. While these therapies can be highly effective for the appropriate stage of disease, LRTs can suffer from a high rate of posttreatment recurrences. Considerations for administration of specific therapies include disease burden and underlying liver function. Recent data on concomitant or adjuvant systemic therapy, with LRT, have the potential to improve disease control and improve outcomes in this high-risk patient population.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.cld.2024.08.003 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Benign Soft Tissue Lesions Responsible for Pain: When and How Should the IR Intervene.
Cardiovasc Intervent Radiol
January 2025
Neuro Vascular Interventional Radiology Program, Department of Radiology, Memorial Sloan Kettering Cancer Center (MSK), New York, NY, 10065, USA.
In most of the cases Interventional Radiology techniques and therapies are proposed for the management of symptomatic soft tissue benign tumors responsible for pain and/or compression symptoms aiming to offer a curative intent by means of tumor necrosis with subsequent symptoms' management and improvement of life quality. The ablative therapies include chemical, thermal and non-thermal approaches while, trans-arterial (chemo)embolization also has a distinct role. Adjunct ancillary techniques should be performed whenever necessary to increase efficacy and safety and avoid or reduce complications.
View Article and Find Full Text PDFAdvanced Management of Patients Undergoing Transcatheter Treatment for Pulmonary Embolism: Evidence-Based Strategies for Optimized Patient Care.
J Clin Med
December 2024
Área del Corazón, Instituto de Investigación Biomédica de Málaga y Plataforma en Nanomedicina (IBIMA Plataforma BIONAND), Hospital Universitario Virgen de la Victoria, Centro de Investigación Biomédica en Red de Enfermedades Cardiovasculares (CIBERCV), Departamento de Medicina UMA, 29010 Malaga, Spain.
Pulmonary embolism (PE) is a life-threatening medical condition caused by the thrombotic occlusion of one or more branches of the lung vasculature, which represents the third most common cause of cardiovascular mortality after myocardial infarction and stroke. PE treatment requires a tailored approach based on accurate risk stratification and personalized treatment decision-making. Anticoagulation is the cornerstone of PE management, yet patients at higher clinical risk may require more rapid reperfusion therapies.
View Article and Find Full Text PDFEmbolic and Ablative Therapy for Hepatocellular Carcinoma.
Clin Liver Dis
February 2025
Division of Gastroenterology and Hepatology, University of Michigan, Ann Arbor, MI, USA. Electronic address:
Article Synopsis
- Locoregional therapies (LRTs) for hepatocellular carcinoma include ablative methods like microwave and radiofrequency ablation, as well as embolic techniques such as transarterial chemoembolization and radioembolization.
- These therapies aim to either cure, bridge, or downstage patients, but they often face challenges with high post-treatment recurrence rates.
- Current research suggests that combining LRTs with systemic therapy could enhance disease control and improve outcomes for patients with liver cancer.
Search trends in the treatment for benign prostatic hyperplasia: A twenty-year analysis.
Asian J Urol
October 2024
Department of Urology, Weill Cornell Medicine, New York, NY, USA.
Objective: Minimally invasive treatments for benign prostatic hyperplasia (BPH) have seen an increase in usage in recent years. We aimed to determine what types of events may influence patient search habits related to surgical BPH treatments.
Methods: Google Trends was used to determine the frequency of searches for different minimally invasive and prostatic ablative treatments for BPH in the United States.
CT/MRI LI-RADS 2024 Update: Treatment Response Assessment.
Radiology
November 2024
From the Department of Radiology, University of Michigan Health System, 1500 E Medical Center Dr, Ann Arbor, MI 48109-5030 (A.A., M.M.L.); Department of Radiology, Memorial Sloan Kettering Medical Center, New York, NY (V.C., R.D., H.Y.); Department of Radiology, Northwestern Medical Center, Chicago, Ill (F.H.M., R.J.L.); Department of Radiology, Duke University Medical Center, Durham, NC (M.B.); Department of Radiology, University of California San Diego, San Diego, Calif (C.S., C.Y.K.); Department of Radiology, University of Toronto, Toronto, Ontario, Canada (A.Z.K.); Department of Radiology, Massachusetts General Hospital, Boston, Mass (A.R.K., A.S.B.); Department of Radiology, Mount Sinai Medical Center, New York, NY (E.K.); Department of Radiology, Mayo Clinic Rochester, Rochester, Minn (D.O.); Department of Radiology, Weill Cornell Medical Center, New York, NY (R.A.C.); and Department of Radiology, University of North Carolina at Chapel Hill, Chapel Hill, NC (L.M.B.).
With the rising incidence of hepatocellular carcinoma, there has been increasing use of local-regional therapy (LRT) to downstage or bridge to transplant, for definitive treatment, and for palliation. The CT/MRI Liver Imaging Reporting and Data System (LI-RADS) Treatment Response Assessment (TRA) algorithm provides guidance for step-by-step tumor assessment after LRT and standardized reporting. Current evidence suggests that the algorithm performs well in the assessment of tumor response to arterial embolic and loco-ablative therapies and fair when assessing response to radiation-based therapies, with limited data to validate the latter.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!